Lilly(US:LLY) Prnewswireยท2025-06-16 10:45Core Insights - Eli Lilly and Company announced the availability of Zepbound (tirzepatide) in higher doses (12.5 mg and 15 mg) for $499/month or less through the Zepbound Self Pay Journey Program, making it accessible regardless of insurance status [1][2][3] - Clinical trials showed significant weight loss results for adults with obesity or overweight, with participants on the 15 mg dose losing an average of 48 lbs (~21% weight loss) [1][5][6] - Zepbound is indicated for adults with obesity or overweight with weight-related medical conditions and is also approved for treating moderate-to-severe obstructive sleep apnea [2][9] Pricing and Availability - The complete range of Zepbound single-dose vials will be available, including 2.5 mg ($349 for the first month), 5 mg ($499), 7.5 mg ($599), 10 mg ($699), 12.5 mg ($849), and 15 mg ($1,049), with the first fill and refills within 45 days priced at $499 for higher doses [3][37] - Prescriptions for the new vials can be made starting July 7, with shipments beginning in early August [1][3] Clinical Efficacy - In a 72-week study of adults without diabetes, average weight loss was reported as 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, and 20.9% (48 lbs) for 15 mg, compared to 3.1% (7 lbs) for placebo [5][6] - For adults with diabetes, average weight loss was 12.8% (28 lbs) for 10 mg and 14.7% (33 lbs) for 15 mg [6] Treatment Guidelines - The recommended starting dosage is 2.5 mg taken weekly for four weeks, followed by an increase to 5 mg, with further increments possible [3][4] - Zepbound should be used in conjunction with a reduced-calorie diet and increased physical activity for optimal results [9][11] Company Initiatives - LillyDirect offers resources for appealing coverage denials and submitting letters of medical necessity, enhancing patient access to Zepbound [5][10] - The company emphasizes the importance of treating obesity with the same urgency as other chronic conditions [2][33]